Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2023 Year-End Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Participants on this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call. I would now like to turn the call over to Miranda Peto, BioCardia Investor Relations. Please go ahead, Miranda.

Thank you, Rocco. Good afternoon and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, PhD, President and Chief Executive Officer and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address BioCardia's expectations for future performance and operational results, references to management's intentions, beliefs, projections, outlook, analyses and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products, technologies and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors and cautionary statements described in BioCardia's report on Form 10-K filed with the SEC this morning. The content of this call contains time-sensitive information that is accurate only as of today, March 27, 2024. Except as required by law, the company disclaims any obligation to publicly update or revise any information to reflect events or circumstances that may occur after this call. It is now my pleasure to turn the call over to Peter Altman, PhD, BioCardia's President and CEO. Peter, please go ahead.

Thank you, Miranda, and good afternoon to everyone on the call. BioCardia's current efforts are focused on advancing its autologous and allogeneic cell therapy platforms to treat significant unmet cardiovascular diseases, specifically ischemic heart failure and chronic myocardial ischemia. All of our cell-based therapies involve local delivery of the therapeutic to the heart or lungs, where we intend them to act locally. Our lead CardiAMP autologous cell therapy is targeted to treat ischemic heart failure of reduced ejection fraction. Today, heart failure of reduced ejection fraction remains a significant unmet clinical need as none of the recently approved therapies reduce mortality, which remains at approximately 10% per year. To put this into context, it has been reported that heart failure is as malignant as some common cancers. Men with heart failure have a worse five-year survival than do men with either prostate or bladder cancer. Women with heart failure have been shown to have a worse five-year survival than women with breast cancer. Heart failure also impacts more than 5 million patients in the United States and is growing. In our lead CardiAMP cell therapy, the patient has cells taken from their bone marrow, processed at point of care in our disposable cell processing kit and delivered to our minimally invasive catheter system to targeted regions around damage in the heart. We now have three clinical trials in treatment for heart failure with the CardiAMP cell therapy that lend support for both safety and therapeutic efficacy for patients having ischemic heart failure of reduced ejection fraction. Our recent experience in missing the primary pre-specified endpoint in our cardiac heart failure clinical trial, while not our chosen path, is not a unique experience for those developing therapies for this disease. Our world-class executive steering committee and the distinguished cardiologists on our data safety monitoring board see that the results just presented from the CardiAMP heart failure trial are compelling, as evidenced by our investigators and our Data Safety Monitoring Board continuing to support and be involved in the program. The interim data presentation from the cardiac heart failure trial presented scientifically earlier this month shows a 37% relative risk reduction in heart death equivalents, a 9.2% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events, reduced cardiac arrhythmias, and enhanced heart function in treated patients relative to the control patients. In addition, the available interim data showed that for an important subset of patients who presented at the screening baseline visit with higher levels of NT-proBNP, a well-established biomarker of active heart failure and stress to the heart, the reduction in heart death equivalents was even greater. Of note, all current leading heart failure trials we have looked at require elevated NT-proBNP for patients to be eligible to participate in these trials. In these patients, an analysis of all available data up to two years in the cardiac heart failure trial with a mean of 20 months follow-up shows improvements over controls, including an 86% relative risk reduction in mortality and a 24% relative risk reduction of non-fatal major adverse cardiac and cerebrovascular events. Further, all clinical outcomes included in this subset analysis favor cell therapy including improved quality of life as measured using the Minnesota Living with Heart Failure questionnaire, reduction of NT-proBNP levels, greater six-minute walk test distance and improved echocardiography parameters of left ventricular ejection fraction, left ventricular end-systolic volume, and left ventricular end-diastolic volume. Both the reduced heart death equivalents and improved quality of life outcomes demonstrate statistical significance favoring therapy in this subset analysis. This is the subgroup we have designed the CardiAMP catheter to inflammatory trial around, which is approved by the FDA in December, activated in February and approved for reimbursement by Medicare in March. We continue to monitor patients enrolled in the CardiAMP heart failure clinical study in which both patients and evaluating physicians are blinded to the treatment group and we expect to complete follow-up in this study in October 2024. As we already have more than 90% of the patient follow-up data that we will ultimately have in the final analysis, we don't expect the results to change significantly. This final data on the patients already treated is expected to be provided to Japan's Pharmaceutical and Medical Device Agency toward approval for the indication of ischemic heart failure. Our formal consultation in November 2023 has suggested that if the data remains as good as it currently appears to be at the final analysis, they are inclined to support approval based on this data without requiring a trial in Japan. Subsequent interactions and consultations with Japan's pharmaceutical and medical device agencies are expected. The confirmatory, CardiAMP heart failure II study approved by the FDA in December 2023 is a Phase 3 multicenter, randomized, double-blind controlled study of up to 250 patients with NT-proBNP levels greater than 500 pg/ml at up to 40 centers in the United States. The primary endpoint is an outcomes composite score based on a three-tiered Finkelstein Schoenfeld Hierarchical Analysis. The tiers starting with the most serious events would be Tier 1 all-cause death, including cardiac death equivalents such as heart transplant or left ventricular assist device placement ordered by time to event. Tier 2, non-fatal major adverse coronary and cerebrovascular events. And Tier 3, change from baseline and quality of life at a minimum of 12 months and a maximum of 24 months. The trial as designed has a greater than 90% power or statistical probability of success to meet the primary endpoint based on the cardiac heart failure trial interim results. We are actively working with our heart failure network and leaders in cardiology to enroll and complete this study as soon as possible. We expect additional news throughout the year on this study. Our CardiAMP cell therapy trial for chronic myocardial ischemia or BCDA-02 is a Phase 3 multicenter randomized double-blinded controlled study intended to include up to 343 patients at up to 40 clinical sites. The company expects to complete enrollment in the rolling cohort soon and begin the randomized phase of the trial. A number of leading investigators including both principal investigators in this trial believe this to be the most compelling indication for the CardiAMP autologous cell therapy. Planning for the randomization phase continues based on promising experience in the patients treated to date. Part of this planning includes utilizing the Medicare reimbursement in place for both the control and treatment arms of this investigational therapeutic study to offset the clinical costs. The company's CardiALLO allogeneic cell therapy for ischemic heart failure or BCDA-03 is a Phase 1/2 clinical program encompassing 69 patients. We have reported the first patient enrolled in the fourth quarter of 2024. At the Technology and Heart Failure Therapeutics meeting earlier this month, it was also reported that there have been no adverse events in follow-up. The CardiALLO heart failure study is intended to build on three previous trials of mesenchymal stem cells in ischemic heart failure using the company's proprietary Helix Delivery System, encompassing 93 patients treated with no treatment-emergent serious adverse events and compelling early signals for benefit. This is a precision medicine study as we are focusing this therapy for the first times on patients who have elevated NT-proBNP and elevated high sensitivity C reactive protein, a marker of inflammation that has been reported for patients with heart failure most responsive to immunomodulatory mesenchymal stem cells. Our strategy to advance our CardiALLO allogeneic program is to seek partnerships and grant funding as it will not have the benefit of Medicare reimbursement in the United States. We intend the Phase 2 portion of the study to be performed in both the United States and in Japan where it has the potential to receive conditional approval based on this one trial. In 2023, we evolved our Helix Biotherapeutic Delivery Partnering Business to focus on long-term partnerships where BioCardia shareholders participate meaningfully in the value created. Our Helix transendocardial delivery system is a therapeutic enabling platform for minimally invasive targeted delivery of biologic agents to the heart. This platform enables all of our therapeutic development efforts and empowers a seamless transition from bench to commercialization for partners. Our biotherapeutic delivery partnerships are expected to enhance future treatment options for millions of patients suffering from heart disease, offset the cost of biotherapeutic delivery for our own therapeutic programs and provide our shareholders with meaningful revenue sharing should our partnering efforts contribute to successful therapeutic development. In September 2023, our biotherapeutic delivery partner CellProthera announced completion of enrollment in their Phase 1/2 cell therapy study post-myocardial infarction and results are expected soon. In March of 2024, we announced a biotherapeutic delivery partnership with StemCardia for a long-term partnership to advance StemCardia's investigational pluripotent stem cell product candidate for the treatment of heart failure initially through a Phase 1/2 clinical study. Two additional premier biotherapeutic delivery partnerships are expected in 2024. Our Morph Access Innovations business is based on the steerable catheter systems through which we perform all of our Helix procedures for biotherapeutic intervention. We are working to obtain FDA approval in Q3 2024 for a product family of Morph DNA steerable sheath introducers in a variety of sizes and lengths with clinical indications for use in the heart and peripheral vascular. BioCardia is actively exploring pathways for commercializing these products in the second half of the year. In summary, we have increased confidence in the potential of our autologous CardiAMP cell therapy program in both ischemic heart failure and chronic myocardial ischemia based on the data we have before us. We are focused strategically on advancing these two clinical programs in a cash neutral fashion with the benefit of the Medicare reimbursement we already have in place. Similarly, we are working on securing grants and partnerships around our allogeneic programs to support their continued clinical development and implementing a recurring revenue biotherapeutic delivery partnering model that includes revenue sharing with our experienced world-class team and our Helix biotherapeutic delivery system. In the coming weeks, we anticipate enrollment of patients in our CardiAMP heart failure two confirmatory study and we will be working on a number of business development activities that have the potential to be impactful in our plans for staying listed on NASDAQ. I will now pass the call to David McClung, our CFO, who will review our Q3, Q4 2023 financial results.

Thank you, Peter, and good afternoon, everyone. Revenues were $0.5 million in 2023 compared to $1.4 million in 2022, primarily due to the timing of revenue earned from new and existing collaborative partners, coupled with the fulfillment of performance obligations in 2022. Expenses year-over-year decreased by 9%. Research and development expenses decreased to $7.7 million in 2023 compared to $8.8 million in 2022, primarily due to the completion of enrollment in the cardiac heart failure trial, coupled with reduced expenses in clinical and related supporting functions. Selling, general and administrative expenses were unchanged at $4.4 million in both 2023 and in 2022. Our net loss in 2023 was $11.6 million, compared to $11.9 million in 2022. We used $10 million in cash for operations in 2023, compared to $10.6 million in 2022. And BioCardia ended the year with $1.1 million in cash and cash equivalents, which together with financing proceeds in the first quarter of 2024 provide runway into the second quarter of 2024. As disclosed in our recent SEC filings, the company has received a determination letter from NASDAQ advising us that the company is not in compliance with listing standards and is subject to delisting. BioCardia intends to remain listed in NASDAQ Capital Markets. Accordingly, BioCardia is appealing the decision and has requested a hearing where the company will submit its plan to regain compliance. The appeal has a state suspension of the company securities pending the hearing. This concludes management's prepared comments and we're happy to take questions from attendees.

Thank you. And today's first question comes from Joe Smith at Alpha Street. Please go ahead. Hello, Mr. Smith. Your line is open, sir. And it appears we lost Mr. Smith's connection. Our next question today comes from Brent Pearson, a Private Investor. Please go ahead.

Good afternoon, gentlemen. I saw that in Q4 you filed a $50 million prospectus. Is that planned to get funding through your BCDA-01 and 02 trials for the next few years? Is part of that to be put into a ramp-up if devices get approved or if you get approval in Japan and you need to ramp up production? Could you give us any commentary that would help us understand the intention for that $50 million?

You want to take David?

Well, this is, we have our S3 we had on file that expired in October. This is simply just refreshing our S3 again. So, we have another one on file. It's a typical resource that we want to have available to us, and we'll use it for ATMs and other things as we need.

So, it's more along the lines of bumping along an existing prospectus that you want to keep open. In terms of your capital needs throughout the rest of the year, I assume you're going to look at the market financings as things are apparent and I assume that you don't expect to have a much different capital usage than you had through 2023. Is that something that we can count on?

Joe, these are great questions and as where we are right now, this is actually sort of the eye of the storm. Our ongoing business development activities, as we've shared, interweave with this, and so we are proceeding with really all options on the table and things will evolve in the coming months as we have our discussions with NASDAQ. So, I think that's probably the best way to describe it. As far as your second follow-up question, our cash needs, I would actually say that our cash needs today are modest. We have publicly disclosed that our burn rate has been significantly reduced as we turn down the spend on the clinical trial that we're now doing follow-up on. The spend could go back up as we accelerate in the cardiac heart failure II to be closer to what it was last year, and the variety of partnerships that are coming together could result in non-dilutive reductions in our burn rate. So, these are the forces that are playing here right now. I don't expect a significant increase in the burn rate, even if we had no revenues, primarily because of the Medicare reimbursement and the stage of the third program still in the Phase 1 dose escalation phase, which is more limited. But we are seeking significantly non-dilutive financing for that. And Brent, forgive me, I referred to you as Joe earlier. My apologies.

No worries. I appreciate the color there. I guess my last question was, we had seen that there were some partner developments mentioned in Q2 and Q3. Does the horizon look about the same? Is there any color that you can provide on that front?

Yes. So, I did share that we expect to have two additional biotherapeutic partnerships this year and I even believe we have one targeted to be completed in this next quarter. But I'd have you think about it in this fashion. When we do work with a partner, oftentimes we create a very significant data set that takes a period of a year or two to develop and then they think about how to take that forward into the clinic or they are in a clinic already and they think about how to take that to the next stage of development. And so, each time we partner, we receive revenues, but the amount of resources being spent on the program is far more significant by our partners. One of the things that we're choosing to do is we're focused completely on long-term partnerships. We do not sell delivery systems. We partner. And that means that if there is value created from the collaboration, then we, meaning the BioCardia shareholders, will ultimately benefit from that, even if BioCardia does not actually wind up commercializing alongside our partners in the future, which if we do, the value for our shareholders would be quite significant. And that's really our goal at the end of the day, but we don't if we're going to do the work with a partner, enable them access to our technology and know-how and experienced team, we not only need to get paid for the work we do along the way and the products we provide, but the value creation on the therapeutic side, we also need to participate in. And so that's a new structure that we're having going forward. And it makes sense. It doesn't cause it's a little different, but it doesn't cause anyone any undue concerns.

And our next question today comes from George with no company given. Please go ahead.

Thank you for taking my questions. Peter, I just had actually you just answered most of the you just provided most of the information I have regarding partnerships. But I guess it looks like you picked up an additional partner this year per the press release this afternoon. There were two at the end of last year and it looks like you have and then in the press release, StemCardia came out, but then you have two additional partners lined up for this year. Is that accurate?

Right now, we have, so just a broad-brush stroke, we have our three programs that we're advancing and we have two partners under this structure that we've been public about. There are other folks we do work with that we're not public about, and the other two players are CellProthera and StemCardia. But we have said in the press release in the targeted milestones that we expect to enter into two additional biotherapeutic delivery partnerships in the year ahead. And I think we've also said that the first one of those, we expect to close in Q2 of this year. Now, so that's, and the idea is to create this long-term value and everything that we do is trying to, we have these platforms and the challenge is always how do you create all the value that's inherent in the platform? How do you, so for CardiAMP, it goes into a number of indications or advancing two of those? For our allogeneic platform, it goes in many directions and we're focused on the one where we have the most experience and data, but we've had discussions around taking that into a number of indications already. And the third platform we have is our Helix Biotherapeutic Delivery platform and this biotherapeutic partnering business. And what's nice is the data I shared with our lead program utilizes our Helix platform, and so that safety data is really compelling for folks developing their own cell gene or protein-based therapy for the heart. And these clinical indications we're going after are so enormous that it's in our investors' ethical interest as a group trying to help these patients enabled these partners. I like to say that at the end of the day, if there are two therapeutics competing for the same patient, I think that the market penetration will accelerate because the clinical consideration will be not should I treat or should I not treat, but which should I treat with when and how often will become the new mindset. So that's sort of the nature on the partnering. And then the last piece, this is we're talking partnering and getting value from platforms. Our Helix system uses our state-of-the-art Morph DNA, steerable introducer platform for all of the procedures. So every Helix procedure and every cell therapeutic procedure we're advancing uses our more FDA cleared product, and so we are going to be securing this year a product family based on that design for broad indications in cardiac and peripheral vascular disease and I know it doesn't have the same value proposition as our biotherapeutic development efforts, but it's a way we can take our existing product because it's already FDA cleared and expand that platform design into other indications where it can have value. And I share with you, with a previous version of this, we've done more than 10,000 procedures with our Morph platform. And we had a great relationship with the customer. It just didn't make sense financially. But today, we've done some things that this has potential to have some really nice legs on it. So, it shows you that even though our cash is extremely tight, we are getting enormously valuable things done for shareholders.

I just had one other question regarding BCDA-01 with the interim data that was presented at the Heart Conference this month. There was a reduction in the arrhythmias for the treated group. And I was curious, is there any thought of why that reduction? Where those results came from? I know that was something like the University of Washington had worked on years ago, to try to reduce that with the stem cells. Any thoughts there or that you can provide?

I do. So, George, and by the way, great question. The arrhythmia signal is actually a pretty strong signal in our data and it's remarkable. We presented a safety data, but one of the greatest concerns in this field where people are putting things, cells, genes, and proteins into the heart is the risk of arrhythmias. If you trigger a cardiac arrhythmia, it can actually be life-threatening. That's basically what a heart attack is. It's a cardiac arrhythmia that's caused by an obstruction in a blood vessel. Once your heart starts fibrillating, you have essentially two minutes to live because you're not pumping blood anymore. So, that arrhythmia data is compelling. Our investigators have been quite excited about it. Reduction in cardiac arrhythmias will be a pre-specified secondary endpoint in the cardiac heart failure II trial because that's an efficacy claim in its own right. And you mentioned the group in Seattle, interestingly enough, that's the same group I expect that's behind StemCardia. The idea with some of those other cell types, the great concern has been arrhythmias because when you introduce a cell into the heart that becomes a heart cell, all heart cells have what they call automaticity. That means it can create what's called an ectopic focus and trigger an arrhythmia. The fact that we can go into the heart with our cells in CardiAMP or BCDA-01 and deliver at ten different locations, I think we've shared, let's just say, hundreds of millions of cells and we don't have any issues with arrhythmias, rather we're seeing a great reduction in arrhythmias, which suggests that perhaps—and I'm hypothesizing here because you asked—what's happening is the enhanced microvascular impacts of what we're delivering increases the healthiness of the cells locally so that we're reducing the number of ectopic foci in our patients without trying to make them heart cells. I also note that the reduction in arrhythmia burden that we see in the patients may also support why we have reduced mortality and reduced major adverse cardiac events in these studies. All of these elements are interconnected, but I'm sort of going out on a limb here, and one of the difficulties in medicine is always proving why something is happening in one way. I guess the end result of that signal is it's a positive one. It has excited our investigators, and we think it's quite valuable for these patients.

That's great. That's all for me. Best of luck.

And our next question is from Joe Smith with Alpha Street. Please go ahead.

Good afternoon, everyone. Can you hear me? This is [indiscernible] for Joe [indiscernible]. Thanks for taking my questions. I wanted to ask if you could provide some information on the estimated timelines for data readouts, particularly from the CardiAMP HF2 trial, which requires a minimum follow-up period of 12 months. Is there any possibility of having an interim or preliminary data readout before those time points in 2024?

So, there's always a possibility. Right now, we're focused on enrolling in that trial. My sense is it is a great question, when will everything be done. I think, I would say in 2024 we're going to have the primary readout on BCDA-01, the trial we've just completed, and we're aiming to take that to Japan. I think that's the biggest near-term news, and we'll keep folks posted on how we're doing in enrollment in the CardiAMP Heart Failure II confirmatory study. As I'm sure you can appreciate, we have 20 centers around the United States that have great experience. They can see that they helped their patients in the last trial, and that's very helpful to us in enrollment. We also expect we've done some things in the trial design to eliminate interim visits that we don't see as necessary now that we have such a great safety data set, so the trial will be easier to perform. Also, we have the advantage that COVID is not omnipresent these days, which we think will significantly enhance our enrollment activities. I can share an anecdote that at some of the centers, one of the biggest lead times in contracting a center on a clinical trial is actually the contract itself. Our contract for this study at the centers where we've just been active has potential to be as short as a half a page. That’s a much easier contract to get done. And so, we'll be advancing CardiAMP Heart Failure II, and we'll be sharing as we enroll patients and add sites. Whether or not we introduce an interim analysis is TBD, I'd have you assume for now that we will not, because I think we've got some pretty good clarity on the direction to go with respect to this. We have a lot going on, and implementing that adaptive design review last year was a huge effort, and it was a significant accomplishment by our team even though it did not result in the victory we hoped for, but it provided us with the value proposition we have today that we can draw from a very large data set that we're using and we're on target. We have hypotheses as to why some of the study design issues did not go our way, but we can't prove why things went wrong. We're focused on demonstrating why this therapy is right.

Perfect. That's helpful. Thanks for the update.

And our next question is a follow-up from George. Please go ahead.

Peter, I'm sorry, I forgot if you already mentioned this and maybe I just didn't hear it. Is BioCardia still on track to have a consultation with Japan in the second or third quarter of this year?

We have said that we will have additional consultations with Japan's PMDA. I haven't, I'm not currently tracking exactly when it's going to happen. My focus today has been around the completion of the data, but as we get closer to mid-Q2, we will be assessing when we are going to be meeting with them. It's a process where you need to submit the requisite information, and then they will schedule it a few weeks out. We don't exactly have perfect control over when that occurs, but they've been very sophisticated in all our interactions with PMDA. We've been very impressed by them.

And that concludes our question-and-answer session. I'd like to turn the conference back over to Dr. Peter Altman for closing remarks.

Thank you, Rocco. Our therapeutic candidates and technologies have significant potential to help millions of patients with heart disease. We now have five cardiac biotherapeutic programs in development including our biotherapeutic delivery partners. Each of these programs has the potential to provide meaningful returns for our investors. I thank all of you for participating in today's call, for your interest in BioCardia and the support you provide for our primary mission to treat heart disease. Have a great afternoon.

Thank you, sir. This concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.